• Epilepsy, Interpretation, CSF
• AMPA-R Ab CBA, CSF
• Amphiphysin Ab, CSF
• Anti-Glial Nuclear Ab, Type 1
• Anti-Neuronal Nuclear Ab, Type 1
• Anti-Neuronal Nuclear Ab, Type 2
• Anti-Neuronal Nuclear Ab, Type 3
• CASPR2-IgG CBA, CSF
• CRMP-5-IgG, CSF
• DPPX Ab IFA, CSF
• GAD65 Ab Assay, CSF
• GABA-B-R Ab CBA, CSF
• GFAP IFA, CSF
• LGI1-IgG CBA, CSF
• mGluR1 Ab IFA, CSF
• Neurochondrin IFA, CSF
• NMDA-R Ab CBA, CSF
• Purkinje Cell Cytoplasmc Ab Type Tr
• Purkinje Cell Cytoplasmic Ab Type 2

• Investigating new onset cryptogenic epilepsy with incomplete seizure control and duration of less than 2 years using spinal fluid specimens
• Investigating new onset cryptogenic epilepsy plus 1 or more of the following accompaniments:
• Psychiatric accompaniments (psychosis, hallucinations)
• Movement disorder (myoclonus, tremor, dyskinesias)
• Headache
• Cognitive impairment/encephalopathy
• Autoimmune stigmata (personal history or family history or signs of diabetes mellitus, thyroid disorder, vitiligo, premature graying of hair, myasthenia gravis, rheumatoid arthritis, systemic lupus erythematosus, idiopathic adrenocortical insufficiency) or "multiple sclerosis"
• History of cancer
• Smoking history (20+ pack years) or other cancer risk factors
• Investigating seizures occurring within the context of a subacute multifocal neurological disorder without obvious cause, especially in a patient with past or family history of cancer

Sterile vial/container

Screw-capped polypropylene vial/tube, sterile (Mayo)

Refrigerated (preferred) - 28 days

Frozen - 28 days

Ambient - 72 hrs

• Gross hemolysis
• Gross lipemia
• Gross icterus

Immunofluorescence Assay (IFA), Cell Binding Assay (CBA) and Western Blot (WB), Radioimmunoassay (RIA), and Immunoblot (IB)

See report

Utilization guidelines for neurologic autoimmune panels